Kim, S. Y., Kim, S., Chang, H., Kim, B., Lee, Y. S., Chang, H., & Park, C. S. (2019). Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea. Front Endocrinol (Lausanne).
استشهاد بنمط شيكاغوKim, Soo Young, Seok-Mo Kim, Hojin Chang, Bup-Woo Kim, Yong Sang Lee, Hang-Seok Chang, و Cheong Soo Park. "Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea." Front Endocrinol (Lausanne) 2019.
MLA استشهادKim, Soo Young, et al. "Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea." Front Endocrinol (Lausanne) 2019.